HTR1B and obsessive-compulsive disorder: Gassó et al. 2017 studied HTR1B promoter methylation in eighty-three child and adolescent subjects treated for 12 weeks with fluoxetine for MDD (n = 57), obsessive compulsive disorder (n = 16), and generalized anxiety disorder (n = 10) [78].